Omeprozole therapy in pediatric patients after liver and intestinal transplantation.

Published

Journal Article

BACKGROUND: Proton pump inhibitors such as omeprazole are increasingly used to prevent stress-related gastric bleeding in critically ill patients. In this investigation, the acid-suppressive potency of omeprazole was assessed in one at-risk group, pediatric patients undergoing liver or intestinal transplantation, or both. METHODS: Twenty-two patients ranging in age from 0.9 to 108 months (23.8 +/- 6.5) underwent isolated liver (n = 10) or intestinal (11 with composite liver allografts) transplantation. Omeprazole was delivered in bicarbonate suspension through a nasogastric tube. Therapy was started after surgery at 0.5 mg/kg every 12 hours. Gastric pH monitoring was performed approximately 2 days later. RESULTS: For the entire group, mean gastric pH equaled 6.1 +/- 0.3, the same in recipients of isolated liver and intestinal allografts. Twelve of the 22 patients demonstrated a discontinuous omeprazole effect, that is, dissipation of acid reduction before the next dose. Five of the 12 patients with discontinuous omeprazole effect had mean gastric pH of less than 5 (3.9 +/- 0.4). In 4 of these 5, the omeprazole dosing interval was shortened to every 8 or every 6 hours, resulting in an increase in mean pH to 6.6 +/- 0.2 ( P < 0.01). In the remaining 10 of 22 patients, acid suppression was uninterrupted until the next dose. No patient experienced bleeding attributable to gastric erosion. CONCLUSION: Omeprazole suspended in sodium bicarbonate is an effective acid-suppressing agent in pediatric recipients of liver or intestinal transplant, or both. A dosage of 0.5 mg/kg every 12 hours is sufficient for most patients, but dosing every 6 to 8 hours is required to assure maximal acid suppression in all.

Full Text

Duke Authors

Cited Authors

  • Kaufman, SS; Lyden, ER; Brown, CR; Davis, CK; Andersen, DA; Olsen, KM; Bergman, KL; Horslen, SP; Sudan, DL; Fox, IJ; Shaw, BW; Langnas, AN

Published Date

  • February 2002

Published In

Volume / Issue

  • 34 / 2

Start / End Page

  • 194 - 198

PubMed ID

  • 11840039

Pubmed Central ID

  • 11840039

International Standard Serial Number (ISSN)

  • 0277-2116

Digital Object Identifier (DOI)

  • 10.1097/00005176-200202000-00016

Language

  • eng

Conference Location

  • United States